Summary
Between May 1978 and March 1982, 179 postmenopausal women with operable breast cancer were randomized to receive either adjuvant tamoxifen, 40 mg daily for three years (TAM group), or no further treatment (controls).
The difference in five-year survival rates (61% in the control group, 72% in the TAM group) was not statistically significant. However, there was a significant improvement in disease-free survival in the TAM group (61%) relative to the controls (44%) (p = 0.008). In estrogen receptor positive patients, tamoxifen improved both the disease-free rate (47% controls, 80% with tamoxifen) and the survival rate (63% to 83%). Similar results were observed in progesterone receptor positive patients. In patients that were estrogen receptor negative, tamoxifen modified neither the survival rate nor the disease-free interval.
This is a preview of subscription content, log in via an institution to check access.
References
Kaplan EL, Meier P: Non parametric estimation from incomplete observation. J Am Statist Assoc 53: 457–481, 1958
Fisher B, Redmond C, Brown A, et al: Treatment of primary breast cancer with chemotherapy and tamoxifen. New Engl J Med 305: 1–6, 1981
Fisher B and other NSABP investigators: Treatment of primary breast cancer with L.PAM/5-F.U. and tamoxifen: an interim report. Breast Cancer Res Treat 3 (Suppl): 7–17, 1983
Hubay CA, Pearson OH, Marshall JS, et al: Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial. Cancer 46: 2805–2808, 1980
Pearson OH, Hubay CA, Marshall JS, et al: Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage II breast cancer: five-years results. Breast Cancer Res Treat 3 (Suppl): 61–68, 1983
Pommatau E, Mayer M, Saez S, Clavel M, Zlatoff P, Dutou L, Pasini E: Thérapeutique adjuvante à la chirurgie du cancer du sein chez la femme. Lyon Chir 78: 395–399, 1982
Ribeiro G, Palmer M: Adjuvant tamoxifen for operable carcinoma of the breast: Report of clinical trial by the Christie Hospital and Holtradium Institute. Br Med J 286: 827–830, 1983
Palshof T: Adjuvant endocrine therapy in the management of primary breast cancer. Rev Endocrine-related Cancer 9 (Suppl): 329–346, 1981
Baum M, Brinkley DM, Dossett JA: Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Lancet i: 257–261, 1983
Pritchard KI, Meakin JW, Boyd NF, et al: A randomized trial of adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer.In: Jones SE, Salmon SE: Adjuvant Therapy of Cancer IV. Grune & Stratton, New York, 1984, pp 339–347
Fisher B, Redmond C, Wolmark N, et al: Breast cancer studies of the NSABP: an editorialized overview.In: Salmon SE, Jones SE: Adjuvant Therapy of Cancer III. Grune & Stratton, New York, 1981, pp 359–369
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Delozier, T., Julien, JP., Juret, P. et al. Adjuvant tamoxifen in postmenopausal breast cancer: Preliminary results of a randomized trial. Breast Cancer Res Tr 7, 105–109 (1986). https://doi.org/10.1007/BF01806795
Issue Date:
DOI: https://doi.org/10.1007/BF01806795